» Articles » PMID: 15048790

Immunosuppression Affects the Rate of Recurrent Primary Biliary Cirrhosis After Liver Transplantation

Overview
Journal Liver Transpl
Date 2004 Mar 30
PMID 15048790
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Identifying the risk factors associated with recurrence of primary biliary cirrhosis after liver transplantation may affect immunosuppression and increase understanding of the pathogenesis. Four hundred eighty-five patients with PBC were followed for a median of 79 months after transplantation; histological evidence of recurrence was found in 23%. On multivariate analysis, the only risk factor identified with recurrence was the type of calcineurin inhibitor used. The odds ratio for recurrence on tacrolimus was 2.73 (95% confidence interval: 1.84-4.10) compared with cyclosporine. For those receiving cyclosporine, the median time to recurrence was 123 months and for those on tacrolimus 62 months (P <.001). Reasons for this difference between the 2 calcineurin inhibitors are not clear.

Citing Articles

Type of calcineurin inhibitor and long-term outcomes following liver transplantation in patients with primary biliary cholangitis - an ELTR study.

van Hooff M, de Veer R, Karam V, Adam R, Taimr P, Polak W JHEP Rep. 2024; 6(8):101100.

PMID: 39045337 PMC: 11263784. DOI: 10.1016/j.jhepr.2024.101100.


Recurrence of Primary Disease After Adult Liver Transplant - Risk Factors, Early Diagnosis, Management, and Prevention.

Mehtani R, Rathi S J Clin Exp Hepatol. 2024; 14(6):101432.

PMID: 38975605 PMC: 11222954. DOI: 10.1016/j.jceh.2024.101432.


Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation.

Kim D, Yoon Y, Kim B, Choudhury A, Kulkarni A, Park J Hepatol Int. 2024; 18(2):299-383.

PMID: 38416312 DOI: 10.1007/s12072-023-10629-3.


Post-Transplant Management and Complications of Autoimmune Hepatitis, Primary Biliary Cholangitis, and Primary Sclerosing Cholangitis including Disease Recurrence.

Henson J, King L Clin Liver Dis. 2023; 28(1):193-207.

PMID: 37945160 PMC: 11033708. DOI: 10.1016/j.cld.2023.07.009.


Current understanding of primary biliary cholangitis.

Tanaka A Clin Mol Hepatol. 2020; 27(1):1-21.

PMID: 33264835 PMC: 7820210. DOI: 10.3350/cmh.2020.0028.